A single-center, double-blind, randomized, cross-over, placebo-controlled, single-dose study to investigate glycemic parameters of efficacy during 24 hours, safety/ tolerability and pharmacokinetics of two dose levels of RO4998452 in patients with type 2 diabetes mellitus

Trial Profile

A single-center, double-blind, randomized, cross-over, placebo-controlled, single-dose study to investigate glycemic parameters of efficacy during 24 hours, safety/ tolerability and pharmacokinetics of two dose levels of RO4998452 in patients with type 2 diabetes mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Tofogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 15 Sep 2010 Status changed from recruiting to completed as reported by Roche.
    • 08 Jan 2010 Planned end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 08 Jan 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health)(NCT01044017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top